Mini review on the monkeypox: a new human threat (2007–2022) | ||||
| ERU Research Journal | ||||
| Volume 1, Issue 1, October 2022, Page 93-101 PDF (289.76 K) | ||||
| Document Type: Mini reviews | ||||
| DOI: 10.21608/erurj.2022.267928 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Mohamed Adel Sayed   1; Veronica Nabil2
| ||||
| 1Faculty of Pharmacy, Egyptian Russian University | ||||
| 2faculty of pharmacy, ERU | ||||
| Abstract | ||||
| While the world is still dealing with the coronavirus disease 2019 (COVID-19) pandemic, the emergence of a new outbreak caused by the monkeypox virus has public health officials concerned about whether it will pose a new threat. Human monkeypox is a zoonotic orthopoxvirus that looks like smallpox. Monkeypox virus is a double stranded DNA virus of the genus orthopox viruses, which also includes variola, cowpox, and vaccinia viruses. So far, two clades of monkeypox virus have been identified in Central and West Africa, with the former causing more severe illness. When humans come into contact with infected animals, they become infected with monkeypox. According to reports, the virus can also be transmitted via direct contact (sexual or skin-to-skin), respiratory droplets, and fomites. However, most cases of monkeypox were mild and self-limiting, and there are currently no specific treatments for patients infected with the monkeypox virus. The goal of this brief review is to describe various trials conducted since 2007. | ||||
| Keywords | ||||
| Monkeypox; Virtual screening; Viral; Infection; treatment | ||||
|
Statistics Article View: 264 PDF Download: 183 |
||||
